EA200801046A1 - Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro - Google Patents

Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro

Info

Publication number
EA200801046A1
EA200801046A1 EA200801046A EA200801046A EA200801046A1 EA 200801046 A1 EA200801046 A1 EA 200801046A1 EA 200801046 A EA200801046 A EA 200801046A EA 200801046 A EA200801046 A EA 200801046A EA 200801046 A1 EA200801046 A1 EA 200801046A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cell carcinoma
vitro
transitional cell
invasive method
identifying
Prior art date
Application number
EA200801046A
Other languages
English (en)
Other versions
EA013927B1 (ru
Inventor
Ана Солоага Вильоч
Хосе Луис Кастрильо Диес
Инма Рамос Родригес
Кепа Эскуредо Гарсиа-Галдеано
Антонио Мартинес Мартинес
Лауреано Симон Буэла
Original Assignee
Лабораториос Салват, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лабораториос Салват, С.А. filed Critical Лабораториос Салват, С.А.
Publication of EA200801046A1 publication Critical patent/EA200801046A1/ru
Publication of EA013927B1 publication Critical patent/EA013927B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к неинвазивному способу выявления in vitro переходно-клеточной карциномы мочевого пузыря у индивидуума путем анализа мочи для определения стадии или тяжести этой формы рака или для мониторинга эффекта лечения данного индивидуума, страдающего от этой формы рака.
EA200801046A 2005-10-11 2006-10-10 Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro EA013927B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05384037A EP1775590A1 (en) 2005-10-11 2005-10-11 Non-invasive in vitro method to detect transitional cell carcinoma of the bladder
PCT/EP2006/009768 WO2007042256A1 (en) 2005-10-11 2006-10-10 Non-invasive in vitro method to detect transitional cell carcinoma of the bladder

Publications (2)

Publication Number Publication Date
EA200801046A1 true EA200801046A1 (ru) 2008-10-30
EA013927B1 EA013927B1 (ru) 2010-08-30

Family

ID=35431172

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801046A EA013927B1 (ru) 2005-10-11 2006-10-10 Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro

Country Status (12)

Country Link
US (1) US20090209431A1 (ru)
EP (4) EP1775590A1 (ru)
JP (1) JP2009511028A (ru)
KR (1) KR20080073707A (ru)
CN (1) CN101300491A (ru)
AR (1) AR057153A1 (ru)
AU (1) AU2006301487A1 (ru)
BR (1) BRPI0617256A2 (ru)
CA (1) CA2624581A1 (ru)
EA (1) EA013927B1 (ru)
NZ (1) NZ567440A (ru)
WO (1) WO2007042256A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512401D0 (en) * 2005-06-17 2005-07-27 Randox Lab Ltd Method
ES2323927B1 (es) * 2007-03-30 2010-05-14 Laboratorios Salvat, S.A. Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga.
JP4922057B2 (ja) * 2007-05-02 2012-04-25 国立大学法人山梨大学 自己免疫性膵炎及び劇症１型糖尿病の検査方法及び検査試薬
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919063B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
US9726670B2 (en) 2007-07-19 2017-08-08 Biomerieux Method for the assay of liver fatty acid binding protein, ACE and CA 19-9 for the in vitro diagnosis of colorectal cancer
FR2919064B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919060B1 (fr) 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
DE102008011850A1 (de) * 2008-02-29 2009-09-03 Michael Grzendowski Biomarker für die Diagnose von Hirntumor
CA2725548A1 (en) * 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
WO2010080935A1 (en) * 2009-01-11 2010-07-15 Alper Biotech, Llc Monoclonal antibodies against pcbp-1 antigens, and uses therefor
US20100272640A1 (en) 2009-04-24 2010-10-28 Ozge Alper Monoclonal Antibodies Against PCBP-1 Antigens, and Uses Therefor
TWI390204B (zh) * 2010-02-11 2013-03-21 Univ Chang Gung Biomarker of bladder cancer and its detection method
EP2596365A4 (en) 2010-07-14 2013-12-18 Alper Biotech Llc MONOCLONAL ANTIBODIES TO PCBP1 ANTIGENES AND APPLICATIONS THEREOF
WO2013040758A1 (zh) * 2011-09-20 2013-03-28 深圳华大基因科技有限公司 膀胱移行细胞癌易感性的相关基因及其预测方法和系统
RU2505818C2 (ru) * 2012-01-10 2014-01-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ онкологии" СО РАМН) Способ прогнозирования исходов химиолучевой терапии плоскоклеточных карцином головы и шеи
CN105899953B (zh) * 2013-11-05 2018-09-18 新加坡科技研究局 膀胱癌生物标志物
EP3187878B1 (en) * 2014-08-26 2019-07-31 Keio University Anti-cancer agent sensitivity-determining marker
EP3304082B1 (en) 2015-06-08 2020-05-13 Arquer Diagnostics Limited Methods for analysing a urine sample
ES2911415T3 (es) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Métodos y kits
EP3364188B1 (en) * 2015-10-14 2021-12-01 Public University Corporation Yokohama City University Blood biomarker for use in evaluation of effect of drug therapy on kidney cancer
CN106093397A (zh) * 2016-06-13 2016-11-09 厦门大学 以谷胱甘肽过氧化物酶 3为标志物的乳腺癌诊断试剂盒
KR101782768B1 (ko) * 2016-08-26 2017-09-28 주식회사 피시피아비아이티 신장질환 조기 진단용 바이오마커 sbp1 및 이의 이용
BR112019007257A2 (pt) * 2016-10-11 2019-07-02 Braskem Sa micro-organismos e métodos para a coprodução de etileno glicol e isobuteno

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221621B1 (en) * 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
US20020172987A1 (en) * 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
AU1159601A (en) * 1999-11-03 2001-05-14 Metris Therapeutics Limited Agents implicated in endometriosis
MXPA02008954A (es) * 2000-03-13 2003-02-12 Amgen Inc Regulacion por apolipoproteina a-1 (apo-a-1) de se°alizacion de celula t.
AU2001266759A1 (en) * 2000-06-07 2001-12-17 Genaissance Pharmaceuticals, Inc. Haplotypes of the acp2 gene
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
DE10238046A1 (de) * 2002-08-20 2004-03-04 Giesing, Michael, Prof. Dr.med. Verfahren zum Untersuchen von Körperflüssigkeiten auf Krebszellen, dessen Verwendung, entsprechende Analysekits und Verwendung bestimmter Wirkstoffe zur Behandlung von Krebs
US20040219572A1 (en) * 2002-12-17 2004-11-04 Jie Chen Specific markers for pancreatic cancer
EP2295976A1 (en) * 2003-03-08 2011-03-16 Auvation Ltd Markers for colorectal cancer
EP1784499A4 (en) * 2004-07-23 2007-08-22 Eastern Virginia Med School BIOMARKER FOR BUBBLE CANCER
CA2577601A1 (en) * 2004-08-13 2006-02-16 Indivumed Gmbh Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system

Also Published As

Publication number Publication date
CA2624581A1 (en) 2007-04-19
AU2006301487A1 (en) 2007-04-19
EP2367007A3 (en) 2012-04-18
EP2369349A3 (en) 2012-04-18
AR057153A1 (es) 2007-11-21
CN101300491A (zh) 2008-11-05
WO2007042256A1 (en) 2007-04-19
NZ567440A (en) 2011-12-22
EA013927B1 (ru) 2010-08-30
EP2369349A2 (en) 2011-09-28
EP1934616A1 (en) 2008-06-25
EP2367007A2 (en) 2011-09-21
EP1775590A1 (en) 2007-04-18
US20090209431A1 (en) 2009-08-20
BRPI0617256A2 (pt) 2011-07-19
JP2009511028A (ja) 2009-03-19
KR20080073707A (ko) 2008-08-11

Similar Documents

Publication Publication Date Title
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2007087261A3 (en) Rapid test apparatus
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2010091049A3 (en) Diagnosis and treatment of cancer
UY32698A (es) Marcadores de riesgo para enfermedades cardiovasculares
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
ES2530843T3 (es) Métodos basados en microARN para el diagnóstico de cáncer de páncreas
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2009024691A3 (fr) Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal
WO2011038155A3 (en) Genetic analysis
NZ602369A (en) Anti-cxcr1 compositions and methods
DE602007011566D1 (en) Ankheit
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
JP2006311860A5 (ru)
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
WO2006138219A3 (en) Methods of diagnosis / prognosis of inflammatory conditions
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2009055823A3 (en) Method to predict responsiveness of breast cancer to polyaminetype chemotherapy
PL2035835T3 (pl) Sposoby szybkiej oceny ciężkości urazu
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU